Benzinga | Jan 11, 2022 06:49AM EST

Needham Maintains Buy on Biogen, Lowers Price Target to $328

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $386 to $328.